DrugDashboards

Lumacaftor and Ivacaftor

Lumacaftor and Ivacaftor · LUMACAFTOR 200 mg/1; IVACAFTOR 125 mg/1 · Tablet, Film Coated · Aesica Queenborough Limited

NDC 43798-0004-01 · 1 POUCH in 1 DRUM / 1 BAG in 1 POUCH / 17700 TABLET, FILM COATED in 1 BAG · DRUG FOR FURTHER PROCESSING · View full market →

Bulk ingredient — not a finished product

This NDC is a raw material (drug for further processing) sold to drug manufacturers or compounders, not a product pharmacies dispense. Retail pricing, TE codes, fragility scores, and shortage reports don't apply to bulk listings — those attach to finished products made from this ingredient.

Medicare Part D

All Part D pricing →

Matched to CMS's representative package for this drug (NDC 51167-0809-01) — same generic, strength, and dosage form. CMS prices one NDC per drug concept, not every package.

ⓘ How this was built
Data sources
  • CMS quarterly Prescription Drug Plan Formulary & Pricing files (SPUF)
Method

Negotiated 30-day point-of-sale unit prices and formulary terms aggregated across every unsuppressed Part D and MA-PD plan for the quarter shown. Point of sale means gross of confidential rebates. CMS publishes one representative NDC per drug concept (RxCUI) rather than every package, so these figures come from CMS's representative package for the same drug — matched on generic name, strength, and dosage form. Estimated from MedPAC's program-wide rebate aggregates (June 2023: DIR = 29% of gross Part D spending; brand rebates ≈ 25–40% of gross, generics minimal). Actual rebates are confidential and vary widely by drug — this is a range, not a fact about this drug.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

Plans pay at point of sale
$211.34per unit
middle half $207.21$216.43 · 4,230 plans · Apr 1, 2026
Est. net of rebates
≈ $211.34
generic — rebates are minimal, so net ≈ gross
Coverage & restrictions
77%of plans cover it
tier 5 · prior auth 98% · step therapy 0% · qty limit 94%

*No drug-level rebate is public — the estimate applies MedPAC's program-wide brand rebate range to this drug's gross price. Tracked here for 10 quarters since 2024.

NADAC price per unit

No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.

Supply fragility

Not scored — fragility is computed for NADAC-priced NDCs.

Regulatory

Application
TE code
Approval date
Patents / exclusivity

Shortage history

No FDA shortage reports for this drug or its presentations.

Recalls (this NDC)

No enforcement reports list this package NDC.

Manufacturers of Lumacaftor and Ivacaftor (Tablet, Film Coated)

LabelerStrengthFirst seenLast seen
Aesica Queenborough LimitedLUMACAFTOR 200 mg/1; IVACAFTOR 125 mg/1Aug 20, 2026Sep 3, 2026
Vertex Pharmaceuticals IncorporatedLUMACAFTOR 200 mg/1; IVACAFTOR 125 mg/1Aug 26, 2026Sep 2, 2026
Vertex Pharmaceuticals IncorporatedLUMACAFTOR 100 mg/1; IVACAFTOR 125 mg/1Aug 26, 2026Sep 2, 2026
Aesica Queenborough LimitedLUMACAFTOR 125 mg/1; IVACAFTOR 200 mg/1Jul 22, 2026Aug 19, 2026
Vertex Pharmaceuticals IncorporatedLUMACAFTOR 125 mg/1; IVACAFTOR 100 mg/1Jul 22, 2026Aug 19, 2026
Vertex Pharmaceuticals IncorporatedLUMACAFTOR 125 mg/1; IVACAFTOR 200 mg/1Jul 22, 2026Aug 19, 2026
Aesica Queenborough LimitedIVACAFTOR 125 mg/1; LUMACAFTOR 200 mg/1Jul 15, 2026Jul 15, 2026
Vertex Pharmaceuticals IncorporatedIVACAFTOR 125 mg/1; LUMACAFTOR 200 mg/1Jul 15, 2026Jul 15, 2026
Vertex Pharmaceuticals IncorporatedIVACAFTOR 125 mg/1; LUMACAFTOR 100 mg/1Jul 15, 2026Jul 15, 2026

Roster from daily NDC Directory diffs — first/last seen dates start July 2026.

Cite this page

DrugDashboards, "Lumacaftor and Ivacaftor — NDC 43798-0004-01," retrieved September 3, 2026, https://drugdashboards.com/drug/43798000401.

Free to cite with attribution — see how the data is put together.